Orthocell Ltd (ASX:OCC) managing director Paul Anderson updates Proactive Investors on the company’s positive pre-clinical study results for CelGro nerve regenerative treatment.
The results validate claims that the technique can deliver higher quality nerve repair, compared to existing methods.
Results also showed the use of CelGro in rats restored nerve fibres to complete regeneration, with these being indistinguishable from normal nerve histology.
Price: $0.43
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HERE
Mining
Mining
Mining
Mining Capital's Alastair Ford discusses the planned slow down in production from Kazatomprom (LON:KAP). The miner's looking to cut output from its Kazakh mines by around 20% through to 2021. He says that extends the timeframe of its previous production curtailment by a further year, and...
Mining
Tempus Resources acquires advanced high-grade Blackdome-Elizabeth...
Mining
Lithium Power International forges ahead with Australia assets and...
